Search This Blog

Monday, January 28, 2019

Crispr Therapeutics downgraded to Neutral from Buy at Goldman Sachs


Goldman Sachs analyst Salveen Richter downgraded Crispr Therapeutics to Neutral and cut his price target for the shares to $40 from $78.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)